Should we treat all primary prevention patients with statins?
- 33 Downloads
3-Hydroxy-3-methylglutary coenzyme A (HMG-CoA) reductase inhibitors have been shown to reduce cardiac events in different high-risk and medium-risk patient groups. Although there are other medications to lower cholesterol, evidence that these agents will provide protection from initial cardiac events is limited or does not exist. Also, although many physicians advocate combining second agents with statins to improve certain lipid fractions, evidence of improved reduction of initial cardiac events from these combinations is also lacking. Therefore, aggressive use of HMG-CoA reductase inhibitors remains the proven treatment to treat lipid abnormalities in primary patients.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 11.Ridker PM, for the JUPITER Study Group: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity c-reactive protein: rationale and design of the JUPITER Trial. Circulation 2003, 108:2292–2297.CrossRefGoogle Scholar
- 12.Crestor Outcomes Study JUPITER Closes Early Due To Unequivocal Evidence of Benefit [press release]. London, UK: AstraZeneca; March 31, 2008.Google Scholar
- 14.Gotto AM: Contemporary Diagnosis and Management of Lipid Disorders, edn 3. Newtown, PA: Handbooks in Health Care; 2004:216.Google Scholar
- 23.BIP Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary heart disease. Circulation 2000, 102:21–36.Google Scholar
- 30.Zetia [package insert]. North Wales, PA: Merck-Schering-Plough Pharmaceuticals; 2007.Google Scholar
- 31.Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial [press release]. North Wales, PA: Merck/Schering-Plough Pharmaceuticals; January 14, 2008.Google Scholar
- 35.Gisnberg HN, Bonds DE, Lovato LC, et al.: Evolution of the lipid trial protocol of the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol 2007, 99:56i–67i.Google Scholar
- 36.Niacin plus statin to prevent cardiovascular events (AIM-HIGH). Available at: http://www.clinicaltrials.gov/ct/show/NCT00120289. Accessed on September 2, 2008.
- 40.West of Scotland Coronary Prevention group: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440–1445.Google Scholar
- 41.IDEAL: Lowering triglycerides in stable statin-treated CHD patients does not provide benefit [press release]. Heart wire/Cardiometabolic Risk; May 2, 2008.Google Scholar